ESTRO 2022 | The future of radiotherapy for prostate cancer
David Dearnaley, MA, MD, FRCP, FRCR, The Institute of Cancer Reseach and The Royal Marsden NHS Foundation Trust, London, UK, gives us his highlights from ESTRO 2022 and discusses recent advances and future directions for radiotherapy in both metastatic and localised prostate cancer. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.
Disclosures
Prof Dearnaley declares personal fees through the Rewards to Discoverer’s Scheme from The Institute of Cancer Research which receives royalty income from abiraterone, support from Cancer Research UK Program Grants C33589/A19727 “Advances in Physics for Precision Radiotherapy” and honoraria for advisory boards from Janssen. In addition, Prof Dearnaley has a patent EP1933709B1 issued for a localisation and stabilization device.
